Table 3

Summary of short- (week 8) and long-term (week 24) primary efficacy variables in intention-to-treat sample using the last observation carried forward method

Variable Baseline adjusted mean Adjusted mean change from baseline to week 8 Adjusted mean change from baseline to week 24
Placebo Venlafaxine ER Placebo Venlafaxine ER
37.5 mg 75 mg 150 mg 37.5 mg 75 mg 150 mg
HRSA, Hamilton Rating Scale for Anxiety; HAD, Hospital Anxiety and Depression scale; CGI—I, Clinical Global Impression of Improvement.
1.Significantly different from placebo (P<0.017).
2.Significantly different from 37.5 mg of venlafaxine (P<0.017).
3.Results for CGI—I presented as a week-8 and week-24 adjusted mean value.
HRSA total 26.5 -10.1 -12.0 -13.81 -14.51 -11.0 -13.81 -15.51 -16.41
HRSA psychic anxiety 14.7 -5.3 -6.5 -7.61 -8.01,2 -5.6 -7.61 -8.51 -9.21,2
HAD anxiety sub-scale 13.2 -3.0 -4.41 -5.91,2 -6.11,2 -3.1 -5.21 -6.31 -7.11,2
CGI—I3 2.7 2.5 2.11 2.01,2 2.6 2.3 1.91 1.91